A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 40-F for FY2025, filed Mar 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MSLE SEC filings page.
This page shows Satellos Bioscience Inc. (MSLE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (40-F and 6-K reports).
Financial Health Signals
We do not publish a peer-relative financial health score for Satellos Bioscience Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Satellos Bioscience Inc. passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Satellos Bioscience Inc. reported a net loss of $24.9M while operations used $23.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Satellos Bioscience Inc. reported a net loss of $24.9M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Satellos Bioscience Inc. earned -$1.70 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Satellos Bioscience Inc. recorded an outflow of $23.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Satellos Bioscience Inc. held $9.8M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Satellos Bioscience Inc.'s ROE was -89.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 45.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Satellos Bioscience Inc. invested $18.4M in research and development in fiscal year 2025. This represents an increase of 28.3% from the prior year.
Satellos Bioscience Inc. invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 50.0% from the prior year.
Not reported for fiscal year 2025.
MSLE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, SG&A Expenses, EBITDA, Interest Expense.
MSLE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
MSLE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
MSLE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Satellos Bioscience Inc. MSLE | FY2025 | N/A | -$24.9M | N/A | $137.3M | — |
| Armata Pharmaceuticals, Inc. ARMP | FY2025 | N/A | -$173.8M | N/A | $111.2M | — |
| Compass Therapeutics, Inc. CMPX | FY2025 | $0 | -$66.5M | N/A | $119.1M | — |
| Sionna Therapeutics, Inc. SION | FY2025 | N/A | -$75.3M | N/A | $141.1M | — |
| ALX Oncology Holdings Inc. ALXO | FY2025 | N/A | -$101.7M | N/A | $138.3M | — |
| NeOnc Technologies Holdings, Inc. NTHI | FY2025 | $40K | N/A | N/A | $131.0M | — |
Where Satellos Bioscience Inc. Ranks
Frequently Asked Questions
No, Satellos Bioscience Inc. (MSLE) reported a net loss of $24.9M in fiscal year 2025.
Satellos Bioscience Inc. (MSLE) has a return on equity of -89.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Satellos Bioscience Inc. (MSLE) recorded an outflow of $23.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Satellos Bioscience Inc. (MSLE) recorded an outflow of $23.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Satellos Bioscience Inc. (MSLE) had $31.9M in total assets as of fiscal year 2025, including both current and long-term assets.
Satellos Bioscience Inc. (MSLE) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Satellos Bioscience Inc. (MSLE) invested $18.4M in research and development during fiscal year 2025.
Satellos Bioscience Inc. (MSLE) had a current ratio of 7.77 as of fiscal year 2025, which is generally considered healthy.
Satellos Bioscience Inc. (MSLE) had a liabilities-to-equity ratio of 0.15 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Satellos Bioscience Inc. (MSLE) had a return on assets of -78.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Satellos Bioscience Inc. (MSLE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $137.3M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Satellos Bioscience Inc. (MSLE) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $137.3M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Satellos Bioscience Inc. (MSLE) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Satellos Bioscience Inc. (MSLE) reported a net loss of $24.9M while operations used $23.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.